Testimony to FDA on VICTOZA

Endocrine Society Submitted Testimony to the Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee 

"Recent advancements in science have proven effective in reducing co-morbidities associated with the disease and have the potential to reduce the economic burden of diabetes on the healthcare system. Because each person faces unique challenges in the management and severity of their diabetes, it is important that a variety of therapeutic options are available. The Society urges the FDA to give fair consideration of new options in combating this disease and to expedite the approval process for emerging therapies that, based on safety and efficacy data, have the potential to reduce complications and impact the progression of diabetes."

Read the Full Testimony

Policy Communications